Neuropathic Pain Market Research
Neuropathic pain results from damage to or dysfunction of the peripheral or central nervous system, rather than stimulation of pain receptors.
As per research it is estimated that the global neuropathic pain market will reach a value of $4.8 billion in 2008. This market is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4.3% from $4.8 billion in 2008 to $6.5 billion in 2015. It is believed that this growth will be supported by the increase in the aging population, increased treatment seeking behavior and increased uptake of the current products. The diagnosis rate remains as one of the barriers for the growth of the market and the available treatment options are moderately successful in meeting the market demand.
The Neuropathic Pain drug therapy market research report provides insight into the pipeline status of neuropathic pain therapeutics by company and by stage, as well as a summary of the latest news and developments in this area. In addition to new developments and disease specific pipeline projects, the listed reports also contain extensive information in tabular format on a company’s full product pipeline, and products by phase of development with regard to the therapy area. The study also helps in keeping track of the industry-specific competitors and partners by better understanding their product pipeline.
The study basically aims at providing a comprehensive overview of the on-goings of the neuropathic pain drugs market.